Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

CRISPR Therapeutics AG Director's Dealing 2021

Jun 14, 2021

30936_dirs_2021-06-14_71d12ca4-c9bb-4cb6-81cb-4214d6ead73c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2021-06-10

Reporting Person: Fleming Harold Edward (Director)

More from CRISPR Therapeutics AG

Regulatory Filings 2026
May 4
Annual Report 2026
Apr 21
Proxy Solicitation & Information Statement 2026
Apr 21
Director's Dealing 2026
Mar 24
Director's Dealing 2026
Mar 24
Director's Dealing 2026
Mar 24
Director's Dealing 2026
Mar 24
Director's Dealing 2026
Mar 17
Director's Dealing 2026
Mar 17
Director's Dealing 2026
Mar 17
View all filings →